Volume 66, Issue 1, Pages (July 2014)

Slides:



Advertisements
Similar presentations
Prof Stephen Langley Professor of Urology St Luke’s Cancer Centre, Guildford, UK PGMS, University of Surrey Focal Brachytherapy UK experience.
Advertisements

Volume 53, Issue 3, Pages (March 2008)
Volume 71, Issue 2, Pages (February 2017)
The PSA Era is not Over for Prostate Cancer
Volume 71, Issue 6, Pages (June 2017)
Volume 50, Issue 1, Pages (July 2006)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 58, Issue 4, Pages (October 2010)
Volume 52, Issue 3, Pages (September 2007)
Volume 70, Issue 1, Pages (July 2016)
Testosterone Therapy in Men With Prostate Cancer
Volume 56, Issue 6, Pages (December 2009)
Volume 191, Issue 6, Pages (June 2014)
Systematic Review of the Efficacy and Safety of High-Intensity Focussed Ultrasound for the Primary and Salvage Treatment of Prostate Cancer  Marisa Warmuth,
Volume 74, Issue 4, Pages (October 2018)
Volume 13, Issue 6, Pages (June 2012)
Volume 61, Issue 6, Pages (June 2012)
Volume 62, Issue 5, Pages (November 2012)
Potential and Limitations of Diffusion-Weighted Magnetic Resonance Imaging in Kidney, Prostate, and Bladder Cancer Including Pelvic Lymph Node Staging:
Volume 69, Issue 2, Pages (February 2016)
Volume 67, Issue 3, Pages (March 2015)
Volume 199, Issue 1, Pages (January 2018)
Bladder Cancer: Management and Future Directions
Let the Games Begin (with EAU Approval)
Volume 71, Issue 2, Pages (February 2017)
Prostate Cancer Epidemic in Sight?
Volume 65, Issue 6, Pages (June 2014)
Bladder Cancer: A Major Public Health Issue
The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.
Volume 52, Issue 3, Pages (September 2007)
Prostate Cancer Detection: A View of the Future
Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance  Adam B. Weiner, Ruth Etzioni, Scott E. Eggener 
Volume 62, Issue 1, Pages (July 2012)
Volume 70, Issue 4, Pages (October 2016)
Volume 68, Issue 1, Pages (July 2015)
Volume 70, Issue 1, Pages (July 2016)
Prostate Cancer Epidemic in Sight?
The PSA Era is not Over for Prostate Cancer
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 61, Issue 6, Pages (June 2012)
Volume 71, Issue 1, Pages (January 2017)
Volume 68, Issue 6, Pages (December 2015)
Volume 53, Issue 6, Pages (June 2008)
Leonard S. Marks, Jiaoti Huang  European Urology 
Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia
Tillmann Loch, Pat Fox Fulgham  European Urology 
Volume 65, Issue 4, Pages (April 2014)
Volume 62, Issue 3, Pages (September 2012)
Volume 65, Issue 1, Pages (January 2014)
Volume 50, Issue 5, Pages (November 2006)
CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System
Volume 55, Issue 3, Pages (March 2009)
Volume 13, Issue 6, Pages (June 2012)
Testicular Cancer Variations in Time and Space in Europe
Jacques Irani  European Urology Supplements 
Insights into the Relationships between Prostatic Disorders and Their Potential Impact on Future Urologic Practice  Claus Roehrborn  European Urology.
Volume 13, Issue 11, Pages e509-e517 (November 2012)
The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.
Jean J.M.C.H. de la Rosette, Vladimir Mouraviev, Thomas J. Polascik 
Volume 65, Issue 3, Pages (March 2014)
European Urology is “Your” Journal
Thomas Steuber, Matthew Frank O'Brien, Hans Lilja  European Urology 
New Trends in Managing the Prostate Cancer Patient
Volume 66, Issue 1, Pages (July 2014)
Role of Transurethral Resection of the Prostate and Biopsy of the Peripheral Zone in the Same Session after Repeated Negative Biopsies in the Diagnosis.
Systematic Review of Complications of Prostate Biopsy
Does PSA Testing Influence the Natural History of Prostate Cancer?
European Urology Oncology
Volume 54, Issue 1, Pages (July 2008)
Volume 51, Issue 5, Pages (May 2007)
Presentation transcript:

Volume 66, Issue 1, Pages 12-19 (July 2014) Prostate Cancer Tumour Features on Template Prostate-mapping Biopsies: Implications for Focal Therapy  Paras B. Singh, Chukwuemeka Anele, Emma Dalton, Omar Barbouti, Daniel Stevens, Pratik Gurung, Manit Arya, Charles Jameson, Alex Freeman, Mark Emberton, Hashim U. Ahmed  European Urology  Volume 66, Issue 1, Pages 12-19 (July 2014) DOI: 10.1016/j.eururo.2013.09.045 Copyright © 2013 European Association of Urology Terms and Conditions

Fig. 1 Template prostate-mapping biopsies. (a) Biopsies are taken every 5mm through a template brachytherapy grid using a method described by Winston Barzell. Biopsies are still taken every 5mm throughout the prostate, and two biopsies are taken from the same grid coordinate if the prostate is longer than the length of one core biopsy [19]. (b) Regional method used on template-mapping biopsy. Although 5-mm sampling is carried out, the biopsies are batched into 20 zones to limit pathology burdens. The colour coding of individual lesions/zones is based on Kirkham et al. [19]. In this case, index lesion ablation could be targeted to the left peripheral zone lesion and the low-volume, low-grade cancer in zone 20 left untreated. Reprinted from [18] with permission from Elsevier. European Urology 2014 66, 12-19DOI: (10.1016/j.eururo.2013.09.045) Copyright © 2013 European Association of Urology Terms and Conditions

Fig. 2 The morphologic characteristics of localised prostate cancers that were deemed suitable and not suitable for focal therapy: (a) unilateral disease, hemiablation; (b) unifocal disease, unifocal ablation; (c) bilateral bifocal disease, bifocal ablation; (d and e) index lesion with low-volume, low-grade lesion or lesions in contralateral areas, index lesion ablation; (f) bilateral high-volume or high-grade disease, not suitable for focal therapy. European Urology 2014 66, 12-19DOI: (10.1016/j.eururo.2013.09.045) Copyright © 2013 European Association of Urology Terms and Conditions

Fig. 3 Flowchart demonstrating patient population characteristics. TTPM=transperineal template prostate mapping; TRUS=transrectal ultrasound; HIFU=high-intensity focussed ultrasound. European Urology 2014 66, 12-19DOI: (10.1016/j.eururo.2013.09.045) Copyright © 2013 European Association of Urology Terms and Conditions